Reduced neoantigen expression revealed by longitudinal multiomics as a possible immune evasion mechanism in glioma

T Nejo, H Matsushita, T Karasaki, M Nomura… - Cancer immunology …, 2019 - AACR
Immune-based therapies have shown limited efficacy in glioma thus far. This might be at
least in part due to insufficient numbers of neoantigens, thought to be targets of immune …
被引用次数：58 相关文章

Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma

T Nejo, H Matsushita, T Karasaki… - Cancer …, 2019 - pubmed.ncbi.nlm.nih.gov
Immune-based therapies have shown limited efficacy in glioma thus far. This might be at
least in part due to insufficient numbers of neoantigens, thought to be targets of immune …

Reduced neoantigen expression revealed by longitudinal multiomics as a possible immune evasion mechanism in glioma

T Nejo, H Matsushita, T Karasaki… - Cancer …, 2019 - okayama.elsevierpure.com
Immune-based therapies have shown limited efficacy in glioma thus far. This might be at
least in part due to insufficient numbers of neoantigens, thought to be targets of immune …

Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma.

T Nejo, H Matsushita, T Karasaki… - Cancer Immunology …, 2019 - europepmc.org
Immune-based therapies have shown limited efficacy in glioma thus far. This might be at
least in part due to insufficient numbers of neoantigens, thought to be targets of immune …

Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma

T Nejo, H Matsushita, T Karasaki, M Nomura… - Cancer Immunology …, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Immune-based therapies have shown limited
efficacy in glioma thus far. This might be at least in part due to insufficient numbers of …

Reduced neoantigen expression revealed by longitudinal multiomics as a possible immune evasion mechanism in glioma

T Nejo, H Matsushita, T Karasaki… - Cancer …, 2019 - okayama.elsevierpure.com
抄録 Immune-based therapies have shown limited efficacy in glioma thus far. This might be
at least in part due to insufficient numbers of neoantigens, thought to be targets of immune …